The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback